CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 169 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2022. The put-call ratio across all filers is 0.65 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $341,248 | -30.5% | 12,400 | -12.7% | 0.00% | -100.0% |
| Q2 2023 | $491,036 | +156780.5% | 14,200 | +61.4% | 0.00% | – |
| Q1 2023 | $313 | -36.8% | 8,800 | -20.7% | 0.00% | – |
| Q4 2022 | $495 | -100.0% | 11,100 | -77.4% | 0.00% | -100.0% |
| Q2 2022 | $1,369,000 | +51.6% | 49,200 | +88.5% | 0.00% | +100.0% |
| Q1 2022 | $903,000 | -4.1% | 26,100 | +7.9% | 0.00% | -50.0% |
| Q4 2021 | $942,000 | +44.0% | 24,200 | +92.1% | 0.00% | – |
| Q3 2021 | $654,000 | +87.4% | 12,600 | -45.2% | 0.00% | -100.0% |
| Q3 2020 | $349,000 | +26.0% | 23,000 | +3.6% | 0.00% | – |
| Q2 2020 | $277,000 | +1219.0% | 22,200 | +86.6% | 0.00% | – |
| Q1 2020 | $21,000 | -55.3% | 11,900 | -44.7% | 0.00% | – |
| Q3 2019 | $47,000 | -56.5% | 21,500 | -46.6% | 0.00% | – |
| Q2 2019 | $108,000 | -50.9% | 40,252 | -10.0% | 0.00% | – |
| Q1 2019 | $220,000 | – | 44,717 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |